DE122006000017I1 - ASP-B28-Insulinkristalle - Google Patents

ASP-B28-Insulinkristalle

Info

Publication number
DE122006000017I1
DE122006000017I1 DE200612000017 DE122006000017C DE122006000017I1 DE 122006000017 I1 DE122006000017 I1 DE 122006000017I1 DE 200612000017 DE200612000017 DE 200612000017 DE 122006000017 C DE122006000017 C DE 122006000017C DE 122006000017 I1 DE122006000017 I1 DE 122006000017I1
Authority
DE
Germany
Prior art keywords
asp
insulin crystals
crystals
insulin
protamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE200612000017
Other languages
English (en)
Inventor
Per Balschmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK93727A external-priority patent/DK72793D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE122006000017I1 publication Critical patent/DE122006000017I1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE200612000017 1993-06-21 1994-06-21 ASP-B28-Insulinkristalle Pending DE122006000017I1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK93727A DK72793D0 (da) 1993-06-21 1993-06-21 Nyt produkt
US08/127,672 US5547930A (en) 1993-06-21 1993-09-28 AspB28 insulin crystals
PCT/DK1994/000246 WO1995000550A1 (en) 1993-06-21 1994-06-21 Aspb28 insulin crystals

Publications (1)

Publication Number Publication Date
DE122006000017I1 true DE122006000017I1 (de) 2006-06-29

Family

ID=26064536

Family Applications (4)

Application Number Title Priority Date Filing Date
DE2001199011 Active DE10199011I2 (de) 1993-06-21 1994-06-21 ASP-B28-Insulinkristalle.
DE69416409T Expired - Lifetime DE69416409T2 (de) 1993-06-21 1994-06-21 Asp-b28-insulinkristalle
DE200612000015 Pending DE122006000015I1 (de) 1993-06-21 1994-06-21 Asp-B28-Insulinkristalle
DE200612000017 Pending DE122006000017I1 (de) 1993-06-21 1994-06-21 ASP-B28-Insulinkristalle

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE2001199011 Active DE10199011I2 (de) 1993-06-21 1994-06-21 ASP-B28-Insulinkristalle.
DE69416409T Expired - Lifetime DE69416409T2 (de) 1993-06-21 1994-06-21 Asp-b28-insulinkristalle
DE200612000015 Pending DE122006000015I1 (de) 1993-06-21 1994-06-21 Asp-B28-Insulinkristalle

Country Status (10)

Country Link
EP (1) EP0705275B1 (de)
JP (1) JP2837956B2 (de)
AT (1) ATE176482T1 (de)
AU (1) AU6995794A (de)
DE (4) DE10199011I2 (de)
DK (1) DK0705275T3 (de)
ES (1) ES2130428T3 (de)
GR (1) GR3030130T3 (de)
NL (3) NL300021I2 (de)
WO (1) WO1995000550A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
GB2327424B (en) * 1994-06-16 1999-03-31 Lilly Co Eli Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
AU711428B2 (en) * 1994-06-16 1999-10-14 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
BR9709845B1 (pt) * 1996-06-20 2008-11-18 preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
CA2258099A1 (en) * 1996-06-20 1997-12-24 Novo Nordisk A/S Insulin preparations containing carbohydrates
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
BE1013507A5 (fr) * 1996-11-22 2002-03-05 Lilly Co Eli Formulations d'analogues de l'insuline.
DE69806582T2 (de) * 1997-03-20 2003-02-13 Novo Nordisk As Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
PL340255A1 (en) 1997-10-24 2001-01-29 Lilly Co Eli Non-dissolving insulin compositions
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
EP1444219A1 (de) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituierte piperidine und deren verwendung zur behandlung von krankheiten, die mit dem histamin-h3-rezeptor in zusammenhang stehen
WO2004089470A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
EP1687019B1 (de) 2003-11-20 2017-11-22 Novo Nordisk A/S Für die herstellung und verwendung in injektionsvorrichtungen optimale propylenglykol enhaltende peptidformulierungen
JP5121707B2 (ja) 2005-07-04 2013-01-16 ハイ ポイント ファーマシューティカルズ，エルエルシー 新規医薬
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
BRPI0618649A2 (pt) 2005-11-17 2011-09-06 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
WO2007104786A1 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Mixtures of amylin and insulin
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
SI2049475T1 (sl) 2006-04-24 2012-04-30 Lilly Co Eli Pirolidinoni substituirani s cikloheksilom kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1
CA2659570C (en) 2006-05-29 2015-10-06 High Point Pharmaceuticals, Llc 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2514406A1 (de) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontan dispergierbare Vorkonzentrate mit einem Peptidwirkstoff in einem festen oder halbfesten Träger
JP5628026B2 (ja) 2007-06-01 2014-11-19 ノボ・ノルデイスク・エー／エス 安定した非水性薬学的組成物
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
MX2011005037A (es) 2008-11-21 2011-06-16 High Point Pharmaceuticals Llc Compuestos de adamantilo benzamida.
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
PL3345593T3 (pl) 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
EP3091995B1 (de) 2014-01-09 2024-03-20 Sanofi Stabilisierte pharmazeutische formulierungen von insulin aspart
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
US9895423B2 (en) * 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
EP3229828B1 (de) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2017163159A1 (en) * 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation

Also Published As

Publication number Publication date
EP0705275A1 (de) 1996-04-10
DE69416409D1 (de) 1999-03-18
DE69416409T2 (de) 1999-09-16
JPH08511779A (ja) 1996-12-10
NL300211I1 (nl) 2006-02-01
JP2837956B2 (ja) 1998-12-16
ATE176482T1 (de) 1999-02-15
DE10199011I1 (de) 2001-04-12
DE10199011I2 (de) 2004-10-14
DE122006000015I1 (de) 2006-06-29
WO1995000550A1 (en) 1995-01-05
NL300021I2 (nl) 2006-05-01
GR3030130T3 (en) 1999-07-30
DK0705275T3 (da) 1999-09-20
NL300212I1 (nl) 2006-02-01
AU6995794A (en) 1995-01-17
ES2130428T3 (es) 1999-07-01
EP0705275B1 (de) 1999-02-03
NL300021I1 (nl) 2000-12-01

Similar Documents

Publication Publication Date Title
NL300212I1 (nl) ASP-B28 insulinekristallen.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
WO2000030622A3 (de) Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen
EP1820862A3 (de) Medizinische Präparate zur Behandlung von Alpha-Galaktosidase-A-Mangel
DE59510531D1 (de) Behältnis zur Lagerung und Verabreichung von Injektions-, Infusions- und Diagnostikpräparaten
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
NO931919L (no) Optisk aktivt 5h-pyrrolo(3,4-b)pyrazinderivat, dets fremstilling samt farmasoeytiske preparater inneholdende derivatet
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
IT1274241B (it) Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
TR199903192T2 (xx) Eritropoetin, de�i�tirilmi� hemoglobin i�eren farmasotik kombine m�stahzarlar.
DE68902300T2 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
FI961938A (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE69724453D1 (de) Camptothecine analoga, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen
DK578589A (da) Farmaceutisk praeparat indeholdende labdanterpenoidderivater og pyrimido(6,1-a)isoquinolin-4-onderivater, dets fremstilling og anvendelse
AU1447892A (en) Pharmaceutical preparations for the therapy of tumors containing colchicine as the active principle and methods for the use of the same
EP0418065A3 (en) Dihydrocaffeic acid derivatives, use thereof for medical treatments and pharmaceutical preparations containing same
CA2247998A1 (en) Fragments of cr1 and their use
IT9048026A0 (it) Preparato farmaceutico e/o cosmetico.
ITDP920008A0 (it) Ustion-guariflash/ prodotto terapeutico per ustioni e piaghe infette, abrasioni, irritazioni cutanee, escoriazioni, senza controindicazioni,per uso esterno. farmaco di nuovissima invenzione, inesistente in commercio, tanto in italia che all'estero.
张建慧 My Bracelet
AU4965493A (en) Optically active ureido-acetamide derivative, its preparation and drugs containing same